CONTROL BIONICS LIMITED — Investor Presentation 2025

Nov 12, 2025

==> picture [283 x 93] intentionally omitted <==

Proven neurotech scaling multi-growth global markets

I N V E S T O R P R E S E N T A T I O N J E R E M Y S T E E L E , C E O 1 3 N O V E M B E R 2 0 2 5

C O N T R O L B I O N I C S . C O M | A S X : C B L

==> picture [675 x 435] intentionally omitted <==

I N V E S T M E N T H I G H LI G H T S

==> picture [118 x 39] intentionally omitted <==

Proven tech. Commercial traction. Global scaling.

A validated surface electromyography (sEMG) platform delivering real-world outcomes in communication, rehab, and sport — now expanding with global approvals, revenues, and reach.

==> picture [85 x 83] intentionally omitted <==

==> picture [72 x 84] intentionally omitted <==

==> picture [86 x 86] intentionally omitted <==

==> picture [83 x 73] intentionally omitted <==

Global validation and IP moat

Growing core business across major markets

Clear path to scale and profitability

Targeting large, unmet market needs

High-margin, multistream revenue model

25 years R&D. Approved Core retail business and protected in the US, continues to grow in the AU, JP, UK and EU. Rare US, AU, and JP. New HCPCS code unlocks US distributors accelerating wholesale reimbursement. near-term growth. Recent Apple BCI integration.

Near breakeven in the core business, with new verticals unlocking both short and long-term upside.

Non-invasive EMG solutions addressing speech, recovery, and performance across global markets.

Hardware sales, SaaS subscriptions, setup fees, and app-based data services — all powered by a single EMG platform.

==> picture [118 x 39] intentionally omitted <==

Core IP and Products

==> picture [128 x 119] intentionally omitted <==

T E C H N O L O G Y

==> picture [118 x 39] intentionally omitted <==

Our core IP — 20 years of EMG innovation

Proven clinical IP that is now smaller, wireless and wearable.

==> picture [165 x 14] intentionally omitted <==

----- Start of picture text -----

NEUROEDUCATOR
----- End of picture text -----

==> picture [230 x 230] intentionally omitted <==

==> picture [125 x 33] intentionally omitted <==

==> picture [171 x 39] intentionally omitted <==

==> picture [225 x 225] intentionally omitted <==

==> picture [124 x 33] intentionally omitted <==

One of the first prototype systems in the NeuroEDUCATOR series was developed 20 years ago with feedback from Stephen Hawking who trialled our technology for many years.

A wireless, wearable NeuroNode® was first launched in 2017. Using our IP, EMG assists diseased and disabled people in accessing technology for the world’s best communication experience.

Launched in 2023, the NeuroStrip® weighs less than a piece of paper and is a miniature version of our core IP. It’s our main lever for growth with unlimited uses.

T E C H N O L O G Y

==> picture [118 x 39] intentionally omitted <==

EMG technology: how it works

Turning neural signals into action.

==> picture [124 x 143] intentionally omitted <==

==> picture [124 x 34] intentionally omitted <==

==> picture [74 x 111] intentionally omitted <==

==> picture [125 x 34] intentionally omitted <==

==> picture [112 x 30] intentionally omitted <==

----- Start of picture text -----

An EMG signal is
detected.
----- End of picture text -----

==> picture [154 x 80] intentionally omitted <==

==> picture [125 x 82] intentionally omitted <==

==> picture [128 x 49] intentionally omitted <==

----- Start of picture text -----

Our patented code
creates a “switch”
to operate devices
----- End of picture text -----

==> picture [234 x 196] intentionally omitted <==

Your brain sends a

thought like “move my index finger”.

To move your finger, an electrical signal is created and

Electromyography (EMG) is the detection of this signal.

Our core IP uses smart

algorithms to detect, analyse and convert your body’s bioelectrical EMG into code so a user can select an item and operate a device.

Users can type, generate speech, send emails, browse the web, stream entertainment, access social apps, control their environment (lights, electric beds), play with toys, and more.

==> picture [66 x 66] intentionally omitted <==

EMG captures, records and interprets electrical activity produced in your body’s muscles when you move

==> picture [118 x 39] intentionally omitted <==

Progress

==> picture [512 x 66] intentionally omitted <==

A S S I S T I V E C O M M U N I C A T I O N

==> picture [118 x 39] intentionally omitted <==

New integration with Apple’s Brain–Computer Interface (BCI) protocol

We are now the only company in the world with a commercially available product using Apple's BCI tech.

EVOLVING BCI LANDSCAPE

POTENTIAL BENEFITS

• BCIs connect the nervous system to digital or mechanical systems

• Surface EMG captures muscle activity representing neural intent

• sEMG is a non-invasive, practical BCI pathway

• Bridges brain intention – muscle activation – device control

• Greater brand awareness

• Opens new application categories beyond disability

• Accelerates distributor engagement and market reach

• Positions us for faster adoption and global scale

FUNDED BCI SOLUTIONS TODAY

IMAGINE

• Control Bionics has partnered with Apple to integrate Apple’s BCI protocol into its sEMG solution

• By applying Apple’s BCI protocol, CBL can significantly improve the functionality and usability of our solution for users and their carers

A racing game where your muscle movements control the car — flex to accelerate, relax to slow down.

• With CBL’s NeuroNode already FDA and TGA-approved, and funding pathways already established, this BCI solution is available immediately across the world

The Apple integration lets you see your muscle intent directly within Apple’s interface, no extra device needed.

A S S I S T I V E C O M M U N I C A T I O N

==> picture [118 x 39] intentionally omitted <==

Control Bionics BCI demonstration

==> picture [1111 x 625] intentionally omitted <==

A S S I S T I V E C O M M U N I C A T I O N

==> picture [118 x 39] intentionally omitted <==

• NeuroNode® wholesale: Unlocking scale in a $1B+ global market

Our fastest near-term growth lever — now scaling in the US with HCPCS-backed wholesale partners. Global partners are expected to be announced by the end of 2025.

MARKET OPPORTUNITY

PROGRESS

• $1B+ global AAC market (US, EU, AU, JP)

• 55,000+ addressable patients with severe physical impairments in US and EU (e.g. MND, CP, SCI etc)

THE STRATEGY

• NeuroNode-only sales via wholesale distribution partners in the US, UK, and other core markets — with strong distributor interest since the award of NeuroNode’s own rare US HCPCS insurance code.

==> picture [55 x 56] intentionally omitted <==

==> picture [54 x 54] intentionally omitted <==

Multiple US wholesale partners in advanced discussions. Reimbursements now cover over 70% of the U.S. population.

Following NHS roadshows, the NeuroNode has become the “go-to device” for similar US/AU profiles. The UK distributor training, marketing and support model is now replicable across all global markets.

• Faster to scale and less capital-intensive model aligns with reimbursement frameworks and accelerates market penetration.

• Permanent and rare US HCPCS code unlocks Medicare/private payer reimbursement (~USD $4,300/unit) and supports potential revenuesharing with distributors to drive mutual growth.

Multiple European regions are now trialling NeuroNode, and further distribution partnerships are expected during FY26. A funding application was also submitted with HMV in Germany. We expect to receive feedback on this in the next month.

S P O R T S P E R F O R M A N C E

==> picture [118 x 39] intentionally omitted <==

==> picture [324 x 420] intentionally omitted <==

“Never seen this technology before. I could see the results right away! I’ve definitely seen a difference in my performance.”

+16.5 cm vertical gain in 3 weeks using NeuroBounce

— JJ Mandaquit, elite point guard, University of Washington commit

Real trials. Real gains. Real endorsements.

Exceptional initial results. Growing demand. Commercial rollout in motion.

==> picture [55 x 55] intentionally omitted <==

NEUROBOUNCE USA

Outstanding results for first athletes with launch customer, Utah Prep Academy, Princeton College and Nets on Fire.

Continued commercialisation with 4 imminent US NeuroBounce group signings and a focused drive to secure the first 10 NeuroBounce customers across the US and Australia

NEUROBOUNCE AUSTRALIA

==> picture [56 x 56] intentionally omitted <==

Appointed Brayden Mifsud to lead rollout. Brayden is an Exercise Scientist and ex-Netball Australia and AIS High Performance Coach.

Very strong trial results for launch customer - SEDA College:

• All athletes improved their vertical jump by 5+ cm in 4 weeks.

• One athlete gained 14 cm.

• Sprint performance improved across the group.

• SEDA partners with Basketball Victoria, Netball Australia, and Cricket Australia, training within state and national pathways.

R E H A B

==> picture [118 x 39] intentionally omitted <==

Rehab: Trusted by experts. Scaling with innovation.

Japan’s leading stroke rehab centre adopts NeuroStrip® to provide superior outcomes for its patients.

==> picture [54 x 54] intentionally omitted <==

JAPAN: STROKELAB REHAB CENTRE

==> picture [52 x 52] intentionally omitted <==

==> picture [56 x 57] intentionally omitted <==

US & AU: REHAB

• Long-time NeuroNode® customer and R&D partner

• All staff are trained and using NeuroStrip® with patients

• 100-patient clinical study underway with a leading neurologist

• Peer-reviewed paper progressing well on uses in Stroke and Parkinson’s treatment with early results due in coming months

• Currently in Tokyo with recently extended partnership to Osaka.

THe NeuroStrip is now deployed across multiple sites in the U.S. and Australia, receiving highly positive feedback from users relating to ease of use and efficacy.

==> picture [385 x 249] intentionally omitted <==

There is strong interest from Australian clinicians supporting individuals with Dysphagia (a swallowing disorder) with a global market around $5 billion.

S T R A T E G I C F O C U S 2 0 2 6

==> picture [118 x 39] intentionally omitted <==

Continue to focus on growth, diversification and innovation in FY26

• Achieve profitability in core markets: Strengthening the US, Australia, and Japan operations to ensure each market achieves EBITDA and cash flow positivity.

• Scaling the NeuroNode Business – Expanding NeuroNode-only sales across key regions with key strategic distribution relationships.

• NeuroStrip® Expansion – Driving adoption in sports science, rehabilitation, and .

• health diagnostics

• Accelerating growth: Identifying strategic partnerships, acquisitions, and licensing opportunities to more rapidly scale the business.

• Building a high-performance: Strengthening leadership, operations, and execution to support sustainable long-term growth.

==> picture [350 x 582] intentionally omitted <==

R O A D M A P

==> picture [118 x 39] intentionally omitted <==

FY26 Roadmap

Q1 FY26

German HMV (Medicare equivalent) application submitted

First commercial sales of NeuroStrip® rehab

NeuroBounce customers commence in US and Australia

Q2 FY26

Research

partnerships for NeuroStrip® announced

US distribution agreements signed

NeuroBounce Labs Launches

Q3 FY26

Results published from initial NeuroStrip® research projects

Further European NeuroNode® Only partnerships signed

Q4 FY26

Consolidation of software applications

Commence data analysis and machine-learning on NeuroStrip® and NeuroNode® data pools

Apple BCI Integration

F Y 2 5 M A J O R A C H I E V E M E N T S

Approval of HCPCS Insurance Code in U.S Global NeuroNode® distribution agreements and partnerships

Investment in and first sales for NeuroBounce UK rollout with SmartBox

NeuroStrip® research partners and customer trials obtained

C O R P O R A T E

==> picture [118 x 39] intentionally omitted <==

P E O P L E

Experienced leadership

B OA R D

==> picture [109 x 109] intentionally omitted <==

==> picture [116 x 116] intentionally omitted <==

Jeremy Steele Managing Director CEO

Dr Samuel Straface Non Executive Chairman Non Executive Director

==> picture [175 x 116] intentionally omitted <==

==> picture [114 x 114] intentionally omitted <==

Prof Rob Heard Damian Lismore Non Executive Director Non Executive Director

==> picture [109 x 110] intentionally omitted <==

Dr Stephanie Phillips Non Executive Director

==> picture [174 x 116] intentionally omitted <==

Brett Crowley Company Secretary

Shannon Boothroyd

• Over 20 years experience in accounting, auditing and finance roles in the United States and Australia

• Previously held senior finance positions with multinational ASX-listed and technology start-up entities • Holds both Chartered Accountant (Australia) and Certified Public Accountant (US) designations

==> picture [1440 x 80] intentionally omitted <==

Disclaimer

This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The information in this presentation, whether written or verbal, has been prepared without taking into account the commercial, financial or other needs of any individual or organisation.

Certain information may relate to protected intellectual property rights owned by Control Bionics Limited (Control Bionics) and its subsidiaries (together the Group).

While due care has been taken in compiling the information based on the information available to Control Bionics at the date of the presentation material, neither Control Bionics nor its officers or advisors or any other person warrants the accuracy, reliability, completeness or timeliness of the information or guarantees the commercial or investment performance of the Group.

The information does not constitute advice of any kind and should not be relied upon as such. Investors must make their own independent assessment of the Group and undertake such additional enquiries as they deem necessary or appropriate for the own investment purposes. Any and all use of the information is at your own risk.

No representations, warranty or assurance (express or implied) is given or made in relation to any forward looking statement by and person (including Control Bionics). In particular, no representation ,warranty or assurance (express or implied) is given in relation to any underlying assumptions or that any forward looking statement will be achieved. Actual future events may vary materially from the forward looking statements and the assumptions on which the forward looking statements are based.

Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Control Bionics disclaims any obligation or undertaking to disseminate any updates or revisions to any forward looking statements in these materials to reflect any change in expectations to any forward looking statements or any change in events, conditions or circumstances on which and such statement is based. Nothing in these materials shall under any circumstances create an implication that there has be been no change in the affairs of the Group since the date of these materials.

==> picture [118 x 39] intentionally omitted <==

Get In Touch

C O M P A N Y

==> picture [134 x 128] intentionally omitted <==

J E R E M Y S T E E L E C E O C O NT R O L B IO NI C S

j s t e e l e @ c o n t r o l b i o n i c s . c o m + 6 1 4 3 3 2 2 9 4 7 0

C O N T R O L B I O N I C S . C O M | A S X : C B L

I N V E S T O R R E L A T I O N S

==> picture [134 x 128] intentionally omitted <==

J OE D U RA K

E X E C UT IV E D I RE C T O R & F OU ND E R L Y N X A D V I SO R S

j o e @ l y n x a d v i s or s . c o m . a u

• 6 1 4 1 4 4 6 5 5 8 2

==> picture [317 x 588] intentionally omitted <==